Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Will Genentech's Cotellic Survive Alternative Pricing Demands?

This article was originally published in Scrip

Executive Summary

Genentech Inc.'s and Exelixis Inc.'s Cotellic (cobimetinib), a MEK inhibitor, made it across the FDA's finish line on Nov. 10, but now the firms must confront the ultimate test of the drug's success – selling it, which is increasingly becoming more difficult in a climate where payers are becoming more and more demanding about using alternative pricing arrangements.

Advertisement

Related Content

Array Rises As COLUMBUS Clears Phase III Melanoma Hurdle

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register